BioSpace News Archive

Jessica Holmquist has been appointed CFO of international medical imaging IT and cybersecurity company Sectra.

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has appointed Ruth Krestin as Vice President of Portfolio Strategy within TISSIUM.

EsoCap announced that the company has entered into a worldwide, exclusive antibody licensing agreement with Upadia, to develop targeted therapeutics to treat Barrett’s esophagus.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2021.

Humanigen, Inc. outlined the next steps for the development of its lead candidate, lenzilumab, in the prevention of CAR-T therapy related toxicities including ICANS and CRS in patients with relapsed or refractory Non-Hodgkin lymphoma.

Reviva Pharmaceuticals Holdings, Inc. announced the U.S. Food and Drug Administration has notified the Company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, provided a corporate update and highlighted key milestones anticipated in 2022.

Neoleukin Therapeutics, Inc. announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that David Spellman, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference, which will take place virtually January 10-13, 2022.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced corporate and portfolio updates in connection with its participation in the J.P. Morgan Annual Healthcare Conference.